<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161874</url>
  </required_header>
  <id_info>
    <org_study_id>3023</org_study_id>
    <nct_id>NCT02161874</nct_id>
  </id_info>
  <brief_title>Evaluation of Integration Success and Crestal Bone Preservation Biomet 3i's T3 Implant System</brief_title>
  <acronym>OAK</acronym>
  <official_title>A Prospective, Randomized-controlled Evaluation of Biomet 3i's T3 Implant System for Integration Success and the Preservation of Crestal Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the T3 implant system for the preservation of alveolar crestal bone and&#xD;
      the establishment of initial integration. The new surface-treated features of the implant may&#xD;
      contribute to improved soft and hard tissue healing. The success rate of the T3 implant will&#xD;
      be no different than that of the control implant, which possess similar geometry but&#xD;
      different surface treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized-controlled study will enroll qualified patients with partial&#xD;
      edentulism who will be treated with at least two dental implants. Implant sites will be&#xD;
      randomly assigned to receive either a test (T3 implant) or control (Nanotite Certain Tapered&#xD;
      implant) with an 80:20 (test:control) randomization ratio.&#xD;
&#xD;
      All implants will be allowed to integrate without occlusal forces and final restorations will&#xD;
      be cemented thereafter.&#xD;
&#xD;
      Cumulative success rate and crestal bone regression of both treatment groups will be the&#xD;
      primary and secondary study endpoints, respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative success rate</measure>
    <time_frame>1 year</time_frame>
    <description>Implant mobility is assessed by clinical evaluations and correlation to initial placement stability- insertion torque profiles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Crestal bone changes</measure>
    <time_frame>2 years</time_frame>
    <description>Crestal bone regression (amount of bone loss) between the two treatment groups will be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Partial Edentulism</condition>
  <condition>Tooth Disease</condition>
  <arm_group>
    <arm_group_label>T3 with DCD tapered implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T3 with DCD tapered prevail implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nanotite certain tapered implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nanotite Certain tapered implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T3 with DCD tapered Prevail implant</intervention_name>
    <description>T3 with DCD implant with Certain (internal) connection and platform-switch design</description>
    <arm_group_label>T3 with DCD tapered implant</arm_group_label>
    <other_name>T3 with Nanotite</other_name>
    <other_name>T3 with platform switch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nanotite Certain tapered implant</intervention_name>
    <description>Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design</description>
    <arm_group_label>Nanotite certain tapered implant</arm_group_label>
    <other_name>Nanotite tapered certain</other_name>
    <other_name>Non-platform switched</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either sex and any race greater than 18 years of age&#xD;
&#xD;
          -  Patients for whom a decision has already been made to use dental implants for the&#xD;
             restoration of existing edentulism in the mandible or maxilla.&#xD;
&#xD;
          -  Patients must be physically able to tolerate conventional surgical and restorative&#xD;
             procedures.&#xD;
&#xD;
          -  Patients must agree to be evaluated for each study visit, especially the yearly&#xD;
             follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active infection or severe inflammation in the areas intended for&#xD;
             implant placement.&#xD;
&#xD;
          -  Patients with a &gt; 10 cigarette per day smoking habit.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Patients with uncontrolled metabolic bone disease where there is a diagnosis of the&#xD;
             following: Osteomalacia, primary or secondary hyperparathyroidism, renal&#xD;
             osteodystrophy, or Paget's disease of bone.&#xD;
&#xD;
          -  Patients with a history of therapeutic radiation to the head&#xD;
&#xD;
          -  Patients in need of bone grafting at the site of the intended study implant for&#xD;
             augmentation purposes.&#xD;
&#xD;
          -  Patients who are known to be pregnant at the screening visit.&#xD;
&#xD;
          -  Patients with evidence of severe para-functional habits such as bruxing or clenching.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Lewis, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastman Dental Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Tommie VanDeVelde</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Dominique Caspar</name>
      <address>
        <city>Les Bains</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Felix Hanssler</name>
      <address>
        <city>Goppingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Nicholas Lewis</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>edentulism</keyword>
  <keyword>dental implants</keyword>
  <keyword>clinical study</keyword>
  <keyword>endosseous</keyword>
  <keyword>randomized</keyword>
  <keyword>crestal bone level</keyword>
  <keyword>T3</keyword>
  <keyword>Nanotite Certain</keyword>
  <keyword>Nanotite Certain Prevail</keyword>
  <keyword>Tapered</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

